AIM: To investigate the significance of p16 and O(6)-methylguanine-DNA methyltransferase (MGMT) genes promoter hypermethylation and K-ras mutations on colorectal tumorigenesis and progression. METHODS: p16 and MGMT methylation status was examined on 47 tumor samples, and K-ras mutational status was examined on 85 tumor samples. For methylation analysis, a methylation specific PCR (MS-PCR) method was used. RESULTS: p16 and MGMT promoter methylation was found in 51% (24/47) and 43% (20/47) of CRCs, respectively, and the K-ras mutation was found in 44% (37/85) of CRCs. Comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease within a two-year period of observation. Only 27% of patients with simultaneous p16 and MGMT methylation showed the detectable occurrence of metastasis and/or death, compared to 67% of patients without double methylation or with no methylation (3/11 vs 22/33, P < 0.05, chi(2)-test). In addition, p16 and MGMT comethylation showed a trend toward an association with longer survival in patients with CRCs (35.5 +/- 6.0 mo vs 23.1 +/- 3.2 mo, P = 0.072, Log-rank test). Progression of the disease within a two-year period was observed in 66% of patients carrying the K-ras mutation, compared to only 19% of patients with wild type K-ras (29/44 vs 7/37, P < 0.001, chi(2)-test). The presence of the K-ras mutation significantly correlated to shortened overall survival (20.0 +/- 1.9 mo vs 37.0 +/- 1.8 mo, P < 0.001, Log-rank test). The comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease even when K-ras mutations were included in the analysis as an independent variable. CONCLUSION: Our data suggest that comethylation of promoters of p16 and MGMT genes could have a prognostic value in patients with CRC. Specifically, concurrent methylation of both genes correlates with better prognosis.
AIM: To investigate the significance of p16 and O(6)-methylguanine-DNA methyltransferase (MGMT) genes promoter hypermethylation and K-ras mutations on colorectal tumorigenesis and progression. METHODS:p16 and MGMT methylation status was examined on 47 tumor samples, and K-ras mutational status was examined on 85 tumor samples. For methylation analysis, a methylation specific PCR (MS-PCR) method was used. RESULTS:p16 and MGMT promoter methylation was found in 51% (24/47) and 43% (20/47) of CRCs, respectively, and the K-ras mutation was found in 44% (37/85) of CRCs. Comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease within a two-year period of observation. Only 27% of patients with simultaneous p16 and MGMT methylation showed the detectable occurrence of metastasis and/or death, compared to 67% of patients without double methylation or with no methylation (3/11 vs 22/33, P < 0.05, chi(2)-test). In addition, p16 and MGMT comethylation showed a trend toward an association with longer survival in patients with CRCs (35.5 +/- 6.0 mo vs 23.1 +/- 3.2 mo, P = 0.072, Log-rank test). Progression of the disease within a two-year period was observed in 66% of patients carrying the K-ras mutation, compared to only 19% of patients with wild type K-ras (29/44 vs 7/37, P < 0.001, chi(2)-test). The presence of the K-ras mutation significantly correlated to shortened overall survival (20.0 +/- 1.9 mo vs 37.0 +/- 1.8 mo, P < 0.001, Log-rank test). The comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease even when K-ras mutations were included in the analysis as an independent variable. CONCLUSION: Our data suggest that comethylation of promoters of p16 and MGMT genes could have a prognostic value in patients with CRC. Specifically, concurrent methylation of both genes correlates with better prognosis.
Authors: P L Jones; G J Veenstra; P A Wade; D Vermaak; S U Kass; N Landsberger; J Strouboulis; A P Wolffe Journal: Nat Genet Date: 1998-06 Impact factor: 38.330
Authors: J K Wiencke; S Zheng; A Lafuente; M J Lafuente; C Grudzen; M R Wrensch; R Miike; A Ballesta; M Trias Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-06 Impact factor: 4.254
Authors: J T Liang; K J Chang; J C Chen; C C Lee; Y M Cheng; H C Hsu; M S Wu; S M Wang; J T Lin; A L Cheng Journal: Oncology Date: 1999 Impact factor: 2.935
Authors: J M Bhatavdekar; D D Patel; P R Chikhlikar; T I Trivedi; N M Gosalia; N Ghosh; N G Shah; H H Vora; T P Suthar Journal: Ann Surg Oncol Date: 1998-09 Impact factor: 5.344
Authors: Kaori Shima; Katsuhiko Nosho; Yoshifumi Baba; Mami Cantor; Jeffrey A Meyerhardt; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino Journal: Int J Cancer Date: 2011-03-01 Impact factor: 7.396
Authors: Muriel X G Draht; Kim M Smits; Benjamin Tournier; Valerie Jooste; Caroline Chapusot; Beatriz Carvalho; Arjen H G Cleven; Sarah Derks; Kim A D Wouters; Eric J T Belt; Hein B A C Stockmann; Herman Bril; Matty P Weijenberg; Piet A van den Brandt; Adriaan P de Bruïne; James G Herman; Gerrit A Meijer; Françoise Piard; Veerle Melotte; Manon van Engeland Journal: Mol Oncol Date: 2014-02-02 Impact factor: 6.603
Authors: P Mokarram; M Zamani; S Kavousipour; F Naghibalhossaini; C Irajie; M Moradi Sarabi; S V Hosseini Journal: Mol Biol Rep Date: 2012-12-28 Impact factor: 2.316
Authors: Daniel L Worthley; Susan L Woods; Tamsin R M Lannagan; Young K Lee; Tongtong Wang; Jatin Roper; Mark L Bettington; Lochlan Fennell; Laura Vrbanac; Lisa Jonavicius; Roshini Somashekar; Krystyna Gieniec; Miao Yang; Jia Q Ng; Nobumi Suzuki; Mari Ichinose; Josephine A Wright; Hiroki Kobayashi; Tracey L Putoczki; Yoku Hayakawa; Simon J Leedham; Helen E Abud; Ömer H Yilmaz; Julie Marker; Sonja Klebe; Pratyaksha Wirapati; Siddhartha Mukherjee; Sabine Tejpar; Barbara A Leggett; Vicki L J Whitehall Journal: Gut Date: 2018-04-17 Impact factor: 23.059